Short answer
Monopar Therapeutics (MNPR) filed its Q1 2026 10-Q quarterly report on May 14, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $0 with net income of −$4M.
Q1 2026 key financials · XBRL
- Revenue
- $0
- Net income
- −$4M
- −48.3% YoY
- EPS (diluted)
- −$0.46
- −21.1% YoY
Source: XBRL data from the Monopar Therapeutics (MNPR) Q1 2026 10-Q on SEC EDGAR. USD.
Monopar Therapeutics Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY; no approved drugs or operating revenue
- Operating margin not meaningful; operating loss $5.225M vs $3.222M YoY
- Net loss $3.893M vs $2.625M YoY; R&D expense $3.487M vs $1.643M
- Cash, equivalents and investments $137.5M at March 31, 2026; funding expected through December 31, 2027
- Outlook: NDA submission for ALXN1840 expected mid-2026; radiopharmaceutical trials and preclinical MNPR-101-Ac advancement ongoing
Risk Factors
- No risk factors provided in the submitted excerpt
- Quarter-end Rule 10b5-1 activity: no non-employee director or officer arrangements adopted or terminated
- Excerpt contains only Other Information, exhibits, and signatures dated May 14, 2026
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Monopar Therapeutics quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.